Biotech · Private company
HI-Bio, A Biogen Company
Track this companyFree. Adds HI-Bio, A Biogen Company to your Dealase workspace and tells you when its record changes.
Clinical trials40 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline4
- FelzartamabPhase 2 · Immunoglobulin A (IgA) NephropathyClinicalTrials.gov · fetched Nov 12, 2026
- MOR202Phase 2 · Glomerulonephritis, MembranousClinicalTrials.gov · fetched Nov 12, 2026
- FelzartamabPhase 1 · Lupus NephritisClinicalTrials.gov · fetched Nov 12, 2026
- HIB210Phase 1 · Immune System DiseasesClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years OldPHASE1 · COMPLETED · started Nov 1, 2023ClinicalTrials.gov NCT06064929 · fetched Nov 12, 2026
- A Study of Safety and Drug Levels of HIB210 in Healthy VolunteersPHASE1 · COMPLETED · started Jul 6, 2023ClinicalTrials.gov NCT05928585 · fetched Nov 12, 2026
- Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA NephropathyPHASE2 · COMPLETED · started Aug 31, 2021ClinicalTrials.gov NCT05065970 · fetched Nov 12, 2026
- Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN)PHASE1_PHASE2 · COMPLETED · started Oct 15, 2019ClinicalTrials.gov NCT04145440 · fetched Nov 12, 2026